CLINICAL TRIALS PROFILE FOR XALATAN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for XALATAN
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00402493 ↗ | Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops | Completed | Pfizer | N/A | 2006-12-01 | The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops. |
| OTC | NCT00402493 ↗ | Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops | Completed | Philadelphia Eye Associates | N/A | 2006-12-01 | The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for XALATAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00140062 ↗ | Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. | Completed | Pfizer | Phase 4 | 2002-02-01 | The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated. |
| NCT00143429 ↗ | Corneal Versus Conjunctival Delivery Using a Delivery Device | Withdrawn | Pfizer | Phase 2 | 1969-12-31 | Compare the antihypertensive efficacy of three methods for installing Xalatan |
| NCT00143429 ↗ | Corneal Versus Conjunctival Delivery Using a Delivery Device | Withdrawn | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 2 | 1969-12-31 | Compare the antihypertensive efficacy of three methods for installing Xalatan |
| NCT00159653 ↗ | A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma | Completed | Pfizer | Phase 3 | 2005-07-01 | To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12. |
| NCT00159653 ↗ | A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 | 2005-07-01 | To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12. |
| NCT00187577 ↗ | Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata | Completed | University of California, San Francisco | N/A | 2005-06-01 | This is a single center, randomized, investigator-masked study to determine the efficacy and safety of latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata. These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer, darker, and thicker eyelashes with their use. In this study, patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XALATAN
Condition Name
Clinical Trial Locations for XALATAN
Trials by Country
Clinical Trial Progress for XALATAN
Clinical Trial Phase
Clinical Trial Sponsors for XALATAN
Sponsor Name
